GREATER NEW YORK HOSPITAL ASSOCIATION for GREATER NEW YORK HOSPITAL ASSOCIATION
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Labor Issues/Antitrust/Workplace LBR
The Standard Merger and Acquisition Act of 2016 (H.R.4616/S.2584) - support.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN COOPER | — |
Medicare/Medicaid MMM
Graduate Medical Education (GME) issues (including Resident Physician Shortage Reduction Act (H.R.2124/S.1148) - support); provided comments to Congress in response to Energy and Commerce Committee request for input on GME; amendments to the Medicare hospital re-admissions penalty program methodology (providing SES adjustments, fixing the formula flaw), H.R.1343/S.688 - support; proposals to amend the 2 midnight policy - support; hospital issues included in President Obama's FY 16 budget - oppose; hospital issues included in H.R.2, the Medicare Access and CHIP Re-authorization Act of 2015 - support; legislation to create a comprehensive Medicare home infusion benefit (H.R.605/S.275) - support; Strengthening Medicare Advantage through Innovation and Transparency for Seniors (H.R.2570) - oppose; Medicare Inpatient Prospective Payment System FY 2016 proposed rule (CMS 1632-P) - detailed comment letter; legislation to improve the recovery audit contractor program (H.R.2156); Audit and Appeal Fairness, Integrity and Reforms in Medicare Act (AFIRM) - provided comments to the Senate Finance Committee; Ensuring Seniors Access to Local Pharmacies Act of 2015 (H.R.793/S.1190) - support; Pharmacy and Medically Underserved Areas Enhancement Act (H.R.592/S.314) - support; MAC Transparency Act (H.R.244) - support; Medication Therapy Management Act (S.776) - support; CMS-4159-F2 - comments on daily dispensing fees; Medicare Independence at Home Medical Practice Demonstration Improvement Act of 2015 (P.L.114-39) - support; provided comments on the proposed Medicare outpatient prospective payment system rule (CMS-1633-P); Medicare IME Pool Act of 2015 (H.R.3292) - oppose; Strengthening DSH and Medicare through Subsidy Recapture and Payment Reform Act (H.R.3288) - oppose; Medicare Crosswalk Hospital Code Development Act (H.R. 3291) - oppose; sign-on letter to CMS urging it to reconsider negative update for CY 2016 (CMS-1633-P) - support; proposed Medicare and Medicaid cuts as offsets to pay for budget increases, raising the debt ceiling, etc. - oppose; site neutral hospital outpatient cuts and other hospital related provisions included in the Bipartisan Budget Act of 2015 (H.R. 1314) - oppose; legislative proposals and Congressional letters to amend the Bipartisan Budget Acts site neutral hospital outpatient payment cut to grandfather sites under development as well as other legislative changes (support) - advocated for their inclusion in the Consolidated Appropriations Act of 2016 (Omnibus legislation/Senate amendment to H.R. 2029); provided comments to Congress regarding provisions in the Mental Health Reform Act of 2015 (S. 1945), that would reform how health care information for substance abuse patients is shared; met with HHS officials on Medicare and Medicaid issues of importance to the Commonwealth of Puerto Rico and Puerto Rican health care providers; submitted comments on Medicare and Medicaid Programs: Reform of Requirements for Long-Term Care Facilities (CMS-3260-P); Stopping Medication Abuse and Protecting Seniors Act of 2015 (S.1913) - support (with some concerns about pharmacy lock-in policy); hospital issues included in House FY 17 budget - oppose; hosptial issues included in President Obama's FY 17 budget proposal - oppose; provided comments in response to Energy and Commerce Committee request for input on hospital site-neutral issues; Medicaid provisions included in the Common Sense Savings Act of 2016 (H.R.4725) - oppose; provided comments to CMS and Congress regarding the Hospital Compare Star Ratings for hospitals - support for delay and fixing measures; The Fair Medicare Hospital Payments Act of 2016 (H.R. 4428) - oppose.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURA ALFREDO | — |
| JONATHAN COOPER | — |
| KAREN SMOLER HELLER | — |
| TIM JOHNSON | — |
| LEE H PERLMAN | — |
| KENNETH E RASKE | — |
| DAVID C RICH | — |
| KATHLEEN SHURE | — |
| SHARA SIEGEL | — |
| AISLING WARDE ZACCARELLI | — |
| ELISABETH R WYNN | — |
Health Issues HCR
Organ donation issues, including the liver transplant allocation system and in support of new proposed UNOS system; support Ebola funding for hospital preparedness and treatment activities, including NY delegation letter to HHS and calls to HHS and meetings with Administration officials; Ebola funding language including in the Consolidated Appropriations Act of 2016 (Omnibus legislation/Senate amendment to H.R. 2029) - support; support for Zika supplemental funding; The Living Donor Protection Act of 2016 (H.R.4616/S.2584) - support; The Standard Merger and Acquisition Reviews Through Equal Rules Act (H.R. 2745) - support; proposed changes to regulation of Laboratory Developed Tests (FDA-2011-D-0360-Draft Guidance for Industry, Food and Drug Administration Staff and Clinical Laboratories: Framework for Regulatory Oversight of Laboratory Developed Tests) - oppose.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN COOPER | — |
| KENNETH E RASKE | — |
| DAVID C RICH | — |
| BRUCE C VLADECK | — |
| SUSAN C WALTMAN | — |
| ELISABETH R WYNN | — |
Budget/Appropriations BUD
House and Senate Budget Resolutions, provisions relating to Medicare reductions - oppose (H.Con.Res. 27, S.Con.Res.11)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN COOPER | — |
| KENNETH E RASKE | — |
| DAVID C RICH | — |
Pharmacy PHA
Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144; support medical device pricing transparency and prohibition on medical device price "gag clauses"; preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases and support draft reform legislation; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); legislation to create a comprehensive Medicare home infusion benefit (H.R.605/S.275) - support; support reforming the durable medical equipment competitive bidding program; supporting "any willing pharmacy" legislation; promoting access to biosimilars (labeling/interchangeability); 21st Century Cures Act (H.R.6) - general support for overall bill, support final pharmacy lock-in policy, oppose PPSA weakening of existing requirements, oppose Section 4004 treatment of infusion drugs furnished through durable medical equipment; Ensuring Seniors Access to Local Pharmacies Act (H.R.793/S.1190) - support; Pharmacy and Medically Underserved Areas Enhancement Act (H.R.592/S.314) - support; MAC Transparency Act (H.R.244) - support; Medication Therapy Management Empowerment Act (S.776) - support; Strengthening Medicare Advantage Through Innovation and Transparency for Seniors - oppose; FDA-2014-D-1524-0002 - comments, Administration and Capitol Hill meetings on draft guidance on repackaging of certain human drug products by pharmacies and outsourcing facilities; FDA-2014-N-1459 - comments and Capitol Hill meetings on draft MOU addressing certain distributions of compounded human drug products between states and the FDA; proposed changes to the 340B prescription drug program - oppose; 21st Century Cures Act (H.R.6) - support; proposed amendments to 340b program (not ultimately included in H.R.6) - oppose; provide comments on proposed 340b omnibus guidance (RIN 0906 AB08); Stopping Medication Abuse and Protecting Seniors Act of 2015 (S.1913)- support (with some concerns about pharmacy lock-in policy); submitted comments on Management Standards for Hazardous Waste Pharmaceuticals (EPA-HQ-RCRA-2007-0932); meeting with DEA on Controlled Substances Act (21 USC 802); proposed changes to regulation of Laboratory Developed Tests (FDA-2011-D-0360-Draft Guidance for Industry, Food and Drug Administration Staff and Clinical Laboratories: Framework for Regulatory Oversight of Laboratory Developed Tests) - oppose.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN COOPER | — |
| LEE H PERLMAN | — |
| KENNETH E RASKE | — |
| DAVID C RICH | — |
| SHARA SIEGEL New | — |
| AISLING WARDE ZACCARELLI | — |
Affiliated organisations
| Organisation | Location |
|---|---|
| GNYHA SERVICES, INC. | New York, NY, US |
| GNYHA VENTURES, INC. | New York, NY, US |
| INNOVATIX, LLC | New York, NY, US |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.